Abstract
Background: Renal cell carcinoma (RCC) is responsible for 4% of all neoplasms in adults and 80% of all primary renal tumours. In the European Union, there are almost 84000 new cases and 35000 deaths each year due to RCC. In the last five decades, patients with localised RCC will develop recurrence of disease after nephrectomy in about 50% of cases. Considering the number of novel targeted therapies approved in the last years for the treatment of mRCC, there has been great interest to assess the efficacy of the same agents in the adjuvant setting.
Objective: to provide a systematic review of literature on the available data to define whether adjuvant treatment plays a role in the management of RCC.
Methods: A literature search using PubMed was carried out with no date restriction up to November 2016. A computerized search of the abstracts reported at ASCO and ESMO library, and www.clinicaltrial.gov was performed in order to identify relevant unpublished studies and ongoing trials.
Results: the search strategy returned 908 entries: after the exclusion of 886 irrelevant publications, 22 studies were eligible for the systematic review.
Conclusion: Currently, there is no robust evidence for the adjuvant treatment for patients with localized RCC at high risk of recurrence post-nephrectomy and often data are conflicting.
It is necessary to identify new prognostic factors that might better predict the risk of relapse after surgery. The enrolment in adjuvant trials should be encouraged for the identification of selected patients who might benefit from adjuvant treatment.
Keywords: Adjuvant therapy, immunotherapy, kinase inhibitors, m-Tor inhibitors, vaccines, renal cell carcinoma.
Anti-Cancer Agents in Medicinal Chemistry
Title:May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials
Volume: 17 Issue: 12
Author(s): Carlo Messina, Elisa Zanardi*Francesco Boccardo
Affiliation:
- Academic Unit of Medical Oncology, Ospedale Policlinico San Martino, Genoa,Italy
Keywords: Adjuvant therapy, immunotherapy, kinase inhibitors, m-Tor inhibitors, vaccines, renal cell carcinoma.
Abstract: Background: Renal cell carcinoma (RCC) is responsible for 4% of all neoplasms in adults and 80% of all primary renal tumours. In the European Union, there are almost 84000 new cases and 35000 deaths each year due to RCC. In the last five decades, patients with localised RCC will develop recurrence of disease after nephrectomy in about 50% of cases. Considering the number of novel targeted therapies approved in the last years for the treatment of mRCC, there has been great interest to assess the efficacy of the same agents in the adjuvant setting.
Objective: to provide a systematic review of literature on the available data to define whether adjuvant treatment plays a role in the management of RCC.
Methods: A literature search using PubMed was carried out with no date restriction up to November 2016. A computerized search of the abstracts reported at ASCO and ESMO library, and www.clinicaltrial.gov was performed in order to identify relevant unpublished studies and ongoing trials.
Results: the search strategy returned 908 entries: after the exclusion of 886 irrelevant publications, 22 studies were eligible for the systematic review.
Conclusion: Currently, there is no robust evidence for the adjuvant treatment for patients with localized RCC at high risk of recurrence post-nephrectomy and often data are conflicting.
It is necessary to identify new prognostic factors that might better predict the risk of relapse after surgery. The enrolment in adjuvant trials should be encouraged for the identification of selected patients who might benefit from adjuvant treatment.
Export Options
About this article
Cite this article as:
Messina Carlo, Zanardi Elisa*, Boccardo Francesco, May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (12) . https://dx.doi.org/10.2174/1871520617666170213114512
DOI https://dx.doi.org/10.2174/1871520617666170213114512 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
SARS Coronavirus Anti-Infectives
Recent Patents on Anti-Infective Drug Discovery Bladder Cancer: A Simple Model Becomes Complex
Current Genomics Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review
Current Drug Metabolism Review of Dose-intense Platinum and/or Paclitaxel Containing Chemotherapy in Advanced and Recurrent Epithelial Ovarian Cancer
Current Pharmaceutical Design Neonatal Germ Cell Tumors
Current Pediatric Reviews Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry A Short Overview on the Biomedical Applications of Silica, Alumina and Calcium Phosphate-based Nanostructured Materials
Current Medicinal Chemistry Small Molecules for the Activation of Human γ δ T Cell Responses Against Infection
Recent Patents on Anti-Infective Drug Discovery Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design Calreticulin is Differentially Expressed in Invasive Ductal Carcinoma: A Comparative Study
Current Proteomics Water Mapping and Scoring Approaches to Predict the Role of Hydration Sites in the Binding Affinity of PAK1 Inhibitors
Combinatorial Chemistry & High Throughput Screening Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals BMPS and Liver: More Questions than Answers
Current Pharmaceutical Design The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry